Tuesday 31 January 2012
Listen to Siri Sing Backup for the Flaming Lips [SIRI]
Wednesday 25 January 2012
Rowley to receive Japan Prize for her role in the development of targeted cancer therapy
![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 24-Jan-2012[ | E-mail |
Share ] Contact: John Easton
john.easton@uchospitals.edu
773-795-5225
University of Chicago Medical Center
Janet Davison Rowley, MD, the Blum-Riese Distinguished Service Professor of Medicine, Molecular Genetics & Cell Biology and Human Genetics at the University of Chicago, will share the 2012 Japan Prize for Healthcare and Medical Technology with Brian J. Druker, MD, from the Oregon Health and Science University, and Nicholas B. Lydon, PhD, formerly with Novartis. They were chosen for their roles in the development of the first precisely targeted anti-cancer drug, called imatinib (Gleevec).
The three recipients, according to the Japan Prize Foundation's announcement on Jan. 25, "have made significant contributions to society by achieving momentous scientific and technological breakthroughs in creating and promoting new technologies for medical diagnosis and treatment."
They each will receive a Certificate of Merit, a Japan Prize Medal and an equal share of 50 million Japanese yen (approximately $215,000 apiece).
Imatinib is a highly effective leukemia medication with few side effects. Most conventional treatments for cancer have been based on their ability to kill rapidly dividing cells. The challenge has been finding a treatment that doesn't harm healthy cells. A series of discoveries enabled the prize winners to develop a more focused medication, designed to interfere with the specific proteins that cause rapid multiplication of the cells that cause chronic myelogenous leukemia (CML), but without damaging healthy cells.
Rowley, Druker and Lydon were key players in a four-decade sequence of breakthroughs leading to the development of Gleevec. It began in the 1960s when two Philadelphia researchers Peter Nowell and David Hungerford found that patients with CML had an abnormally small chromosome 22 in their tumor cells, which was labeled the "Philadelphia" chromosome.
In 1973, using newly developed methods for visualizing segments of chromosomes, Rowley showed that chromosomes from CML cells did not lose genetic material, but rather they exchanged it, a phenomenon she has described in several types of leukemia.
The Philadelphia chromosome was the result of such a translocation. In patients with CML, a crucial segment of chromosome 22 broke off and moved to chromosome 9, where it did not belong. At the same time, a tiny piece of chromosome 9, which included an important cancer-causing gene, had moved to the breakpoint on chromosome 22. Because of this transfer from one chromosome to another, important genes that regulated cell growth and division were no longer located in their normal positions on the chromosome.
Other scientists used this discovery as a road map to narrow the search for specific genes that were disrupted by chromosome translocations. In 1993, Lydon a medicinal chemist at Ciba-Geigy, later purchased by Novartis began a collaboration with Druker, who had created cellular models of the genetic changes that drive CML. The two physicians developed the lead candidate drug from this program, then known as STI-571, and showed that Lydon's drug exerted powerful effects against Druker's CML cells.
In subsequent clinical trials, led by Druker, imatinib "shocked the world of clinical medicine," according to the Japan Prize Foundation. It demonstrated dramatic clinical effectiveness in reducing leukemia cells, achieving long-term remissions in more than 90 percent of patients with CML. It was approved by the Food and Drug Administration in 2001 and has proved effective against several other cancers caused by similar genetic mechanisms.
"Before the development of the molecularly targeted drug imatinib, CML was a fatal disorder where patients progressed to blastic crisis within a few years and died due to a treatment-refractory acute leukemia," notes the Foundation's Award Citation. The molecular-targeting approach used to develop Imatinib, has given "great hopes for the future of cancer drug development."
For this "extraordinary achievement, the development of a revolutionary therapy for cancers," the Foundation has deemed Rowley, Druker and Lydon "most eminently deserving of the 2012 Japan Prize given to honor contributions in the fields of Healthcare and Medical Technology."
The Japan Prize Presentation Ceremony will be held in April in the presence of Their Majesties, the Emperor and Empress of Japan, with leaders "from every field of endeavor" in attendance.
Rowley, 86, has received many honors, including the Lasker Award, the National Medal of Science and the Presidential Medal of Freedom, the nation's highest civilian honor. In December, the American Society of Hematology honored Rowley and Druker with its 2011 Ernest Beutler Lecture and Prize for their work on CML. Druker and Lydon received the Lasker Award in 2009.
"Janet is a pioneer in what is now called 'translational research,' the direct application of laboratory studies to understanding and treating human disease," said leukemia specialist Richard Larson, MD, professor of medicine at the University of Chicago and one of the prinicipal investigators in the initial trials of imatinib. "She opened a window that allowed us to see the genetic basis of the leukemias and other cancers."
Rowley's contributions to identifying chromosomal abnormalities in leukemias and lymphomas have changed the way these diseases are diagnosed and treated. Today, newer techniques can identify the DNA damage within individual cells, offering a much more precise diagnosis of disease and more effective treatments.
She continues to head an active laboratory at the University of Chicago Medical Center that focuses on the connections between genetic changes and cancer.
###
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 24-Jan-2012[ | E-mail |
Share ] Contact: John Easton
john.easton@uchospitals.edu
773-795-5225
University of Chicago Medical Center
Janet Davison Rowley, MD, the Blum-Riese Distinguished Service Professor of Medicine, Molecular Genetics & Cell Biology and Human Genetics at the University of Chicago, will share the 2012 Japan Prize for Healthcare and Medical Technology with Brian J. Druker, MD, from the Oregon Health and Science University, and Nicholas B. Lydon, PhD, formerly with Novartis. They were chosen for their roles in the development of the first precisely targeted anti-cancer drug, called imatinib (Gleevec).
The three recipients, according to the Japan Prize Foundation's announcement on Jan. 25, "have made significant contributions to society by achieving momentous scientific and technological breakthroughs in creating and promoting new technologies for medical diagnosis and treatment."
They each will receive a Certificate of Merit, a Japan Prize Medal and an equal share of 50 million Japanese yen (approximately $215,000 apiece).
Imatinib is a highly effective leukemia medication with few side effects. Most conventional treatments for cancer have been based on their ability to kill rapidly dividing cells. The challenge has been finding a treatment that doesn't harm healthy cells. A series of discoveries enabled the prize winners to develop a more focused medication, designed to interfere with the specific proteins that cause rapid multiplication of the cells that cause chronic myelogenous leukemia (CML), but without damaging healthy cells.
Rowley, Druker and Lydon were key players in a four-decade sequence of breakthroughs leading to the development of Gleevec. It began in the 1960s when two Philadelphia researchers Peter Nowell and David Hungerford found that patients with CML had an abnormally small chromosome 22 in their tumor cells, which was labeled the "Philadelphia" chromosome.
In 1973, using newly developed methods for visualizing segments of chromosomes, Rowley showed that chromosomes from CML cells did not lose genetic material, but rather they exchanged it, a phenomenon she has described in several types of leukemia.
The Philadelphia chromosome was the result of such a translocation. In patients with CML, a crucial segment of chromosome 22 broke off and moved to chromosome 9, where it did not belong. At the same time, a tiny piece of chromosome 9, which included an important cancer-causing gene, had moved to the breakpoint on chromosome 22. Because of this transfer from one chromosome to another, important genes that regulated cell growth and division were no longer located in their normal positions on the chromosome.
Other scientists used this discovery as a road map to narrow the search for specific genes that were disrupted by chromosome translocations. In 1993, Lydon a medicinal chemist at Ciba-Geigy, later purchased by Novartis began a collaboration with Druker, who had created cellular models of the genetic changes that drive CML. The two physicians developed the lead candidate drug from this program, then known as STI-571, and showed that Lydon's drug exerted powerful effects against Druker's CML cells.
In subsequent clinical trials, led by Druker, imatinib "shocked the world of clinical medicine," according to the Japan Prize Foundation. It demonstrated dramatic clinical effectiveness in reducing leukemia cells, achieving long-term remissions in more than 90 percent of patients with CML. It was approved by the Food and Drug Administration in 2001 and has proved effective against several other cancers caused by similar genetic mechanisms.
"Before the development of the molecularly targeted drug imatinib, CML was a fatal disorder where patients progressed to blastic crisis within a few years and died due to a treatment-refractory acute leukemia," notes the Foundation's Award Citation. The molecular-targeting approach used to develop Imatinib, has given "great hopes for the future of cancer drug development."
For this "extraordinary achievement, the development of a revolutionary therapy for cancers," the Foundation has deemed Rowley, Druker and Lydon "most eminently deserving of the 2012 Japan Prize given to honor contributions in the fields of Healthcare and Medical Technology."
The Japan Prize Presentation Ceremony will be held in April in the presence of Their Majesties, the Emperor and Empress of Japan, with leaders "from every field of endeavor" in attendance.
Rowley, 86, has received many honors, including the Lasker Award, the National Medal of Science and the Presidential Medal of Freedom, the nation's highest civilian honor. In December, the American Society of Hematology honored Rowley and Druker with its 2011 Ernest Beutler Lecture and Prize for their work on CML. Druker and Lydon received the Lasker Award in 2009.
"Janet is a pioneer in what is now called 'translational research,' the direct application of laboratory studies to understanding and treating human disease," said leukemia specialist Richard Larson, MD, professor of medicine at the University of Chicago and one of the prinicipal investigators in the initial trials of imatinib. "She opened a window that allowed us to see the genetic basis of the leukemias and other cancers."
Rowley's contributions to identifying chromosomal abnormalities in leukemias and lymphomas have changed the way these diseases are diagnosed and treated. Today, newer techniques can identify the DNA damage within individual cells, offering a much more precise diagnosis of disease and more effective treatments.
She continues to head an active laboratory at the University of Chicago Medical Center that focuses on the connections between genetic changes and cancer.
###
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2012-01/uocm-rtr012312.php
pearl jam 20 martha marcy may marlene lacuna lacuna paranormal activity 3 trailer paranormal activity 3 trailer oomph
Saturday 21 January 2012
Mitt Romney's Hypocrisy on Keystone XL, Eminent Domain (ContributorNetwork)
COMMENTARY | Mitt Romney drilled into President Barack Obama for rejecting the controversial Keystone XL oil pipeline during last night's CNN Southern Republican Debate.
The former Massachusetts Governor accused Obama of having "to bow to the most extreme members of the environmental movement."
"He turns down the Keystone Pipeline, which would bring energy and jobs to America," Romney said, according to the official debate transcript posted by CNN.
In a statement released on his campaign website Wednesday, Romney made similar comments.
"By declaring that the Keystone pipeline is not in the 'national interest,' the President demonstrates a lack of seriousness about bringing down unemployment, restoring economic growth, and achieving energy independence," he said. "He seems to have confused the national interest with his own interest in pleasing the environmentalists in his political base."
In his jobs plan, Romney promises to "ensure rapid progress on the Keystone XL Pipeline," and to "pave the way for the construction of additional pipelines that can accommodate the expected growth in Canadian supply of oil and natural gas in the coming years."
But Romney's support for the proposed oil pipeline contradicts his answer to a question posed by John Distaso, a veteran political reporter for the Union Leader, at a debate last summer in New Hampshire.
"Should governments at any level be able to use eminent domain for major projects that will reduce America's dependence on foreign oil?" Distaso queried.
"Well, I don't believe that land should be taken -- the power of government to give to a private corporation," Romney responded. "And so, the right of eminent domain is a right which is used to foster a public purpose and public ownership for a road, highways, and so forth. And so my view is, if land is going to be taken for purposes of a private enterprise, that's the wrong way to go."
Beyond the bright lights and shallow rhetoric of the campaign trail, opposition to Keystone XL is hardly limited to radical environmentalists. Even the conservative National Review Online has acknowledged that eminent domain is "an issue brewing that could derail the pipeline."
A report published by the New York Times last fall found that TransCanada, the foreign company behind the Keystone XL project, had already filed eminent domain lawsuits against 56 landowners in Texas and South Dakota.
It's something Mitt Romney should consider before he continues to attack President Obama and environmentalists for opposing the project.
megamind human centipede 2 mla format resistance 3 austin tx us postal service trey songz
Thursday 19 January 2012
Declines in melanoma deaths limited to the most educated
Tuesday, January 17, 2012
A new study from the American Cancer Society finds recent declines in melanoma mortality rates in non-Hispanic Whites in the U.S. mainly reflect declines in those with the highest level of education, and reveals a widening disparity in melanoma mortality rates by education. The authors say the findings call for early detection strategies to effectively target high-risk, low-educated, non-Hispanic White individuals. The study is published Online First by Archives of Dermatology.
Since the early 1990s, overall melanoma mortality rates among Non-Hispanic Whites (ages 25 to 64 years) have been declining in men and women. But it has not been known whether these death rates might differ according to socioeconomic status (SES).
To study whether melanoma death rate trends might differ according to SES, researchers led by Vilma Cokkinides, Ph. D, reviewed death certificates from 26 states, representing approximately 45 percent of the U.S. population. They found melanoma mortality declined about ten percent between over the latest ten-year span (1993-97 to 2003-07) in both men (RR= 0.916, 95% C.I.= 0.878, 0.954) and women (RR = 0.907, 95% C.I.= 0.857, 0.957).
However, declines occurred only among those with at least 13 years of education or more, irrespective of sex. In fact, there were actually non-significant increases among the least educated individuals. As a result, the educational gap in melanoma mortality rates widened by 51.7% in men and by 35.7% in women between the two time periods (1993-97 and 2003-07).
"To our knowledge, this is the first study to document this education gap in melanoma mortality trends among Non-Hispanic Whites in the U.S.," said Dr. Cokkinides. "The reasons for the widening of the educational gap in mortality rates are not yet understood, but we do know the cornerstone of melanoma control is recognizing the signs of melanoma early. Lower socioeconomic status is associated with suboptimal knowledge and awareness of melanoma, inadequate health insurance, and lower rates of skin self-examination or physician screening."
The authors conclude recent declines in melanoma mortality are largely confined to more educated groups, and that an increasingly disproportionate burden of fatal melanoma among low SES populations calls for more vigilant primary and secondary prevention education campaigns directed to high-risk, low SES individuals and the physicians that care for them.
###
American Cancer Society: http://www.cancer.org
Thanks to American Cancer Society for this article.
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
This press release has been viewed 27 time(s).
Source: http://www.labspaces.net/116746/Declines_in_melanoma_deaths_limited_to_the_most_educated
105.1 alex trebek lightsquared jane lynch matt ryan matt ryan real housewives of new york
RIM Is Pushing Really Hard To Be Bought By ... - Business Insider
Research in Motion is currently in talks with just about everybody, hoping to sell parts of, or the entire business, Jonathan Geller at BGR reports.
The number one company on its wish list of acquirers is Samsung, says Geller, citing "a trusted source with knowledge of the situation." That source says co-CEO Jim Balsillie is "going hard" after Samsung.
Samsung is said to be interested in buying RIM for its BlackBerry messenger product, which it would incorporate into Android phones as a way to differentiate itself from all the other Android phone makers. It would also use other BlackBerry features to attract enterprise users.
The sticking point in all conversations involving RIM? Money. RIM's executives want a lot, would-be acquirers want to give up a little.
Geller reports RIM's executives are under the delusion the company is worth $12-$15 billion. Its market cap is currently at $8.5 billion, and arguably the company is actually worth less than that.
Geller has a mixed track records on big scoops, but is generally pretty well dialed in on RIM.
Source: http://www.businessinsider.com/rim-wants-to-be-acquired-by-samsung-says-bgr-2012-1
bill o brien casey anthony leann rimes dakota fanning joseph kennedy iii casey anthony video diary lamarcus aldridge
Wednesday 18 January 2012
Maradona cleared to leave hospital
Associated Press Sports
updated 9:00 a.m. ET Jan. 16, 2012
DUBAI, United Arab Emirates (AP) -Diego Maradona has left a private hospital in Dubai after undergoing surgery to remove kidney stones.
A statement released by the Dubai-based club Al Wasl said the coach and former Argentina great was discharged from the Canadian Specialist Hospital on Monday following his operation Sunday night. It said Maradona will take a day off to rest and recuperate and is expected to return to the club on Wednesday.
Maradona was admitted to the hospital after complaining of abdominal pains.
Maradona coached Al Wasl to a 2-1 victory over Al Ahli on Saturday. The club's next match is Jan. 23.
? 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
advertisement
More newsMan City's road woes over
Edin Dzeko ended Manchester City's two-month road winless streak, scoring on a header in the 22nd minute for a 1-0 victory over Wigan.
Arsenal ouch
Arsenal's slim chance to contend took a serious blow on Sunday when the Gunners lost 3-2 at Swansea.
Source: http://nbcsports.msnbc.com/id/46005016/ns/sports-soccer/
margarito margarito horton hears a who horton hears a who cotto margarito big daddy role models
Thursday 12 January 2012
US: Iran has not yet decided to build nuclear bomb (AP)
WASHINGTON ? Defense Secretary Leon Panetta says Iran is laying the groundwork for making nuclear weapons someday, but is not yet building a bomb and called for continued diplomatic and economic pressure to persuade Tehran not to take that step.
As he has previously, Panetta cautioned against a unilateral strike by Israel against Iran's nuclear facilities, saying the action could trigger Iranian retaliation against U.S. forces in the region.
"We have common cause here" with Israel, he said. "And the better approach is for us to work together."
Panetta's remarks on CBS' Face the Nation, which were taped Friday and aired Sunday, reflect the long-held view of the Obama administration that Iran is not yet committed to building a nuclear arsenal, only to creating the industrial and scientific capacity to allow one if its leaders to decide to take that final step.
The comments suggest the White House's assessment of Iran's nuclear strategy has not changed in recent months, despite warnings from advocates of military action that time is running out to prevent Tehran from becoming a nuclear-armed state.
Iran says its nuclear program is only for energy and medical research, and refuses to halt uranium enrichment
Several Republican candidates have called for a tougher line against Iran, saying they believe it is committed to building the bomb. "If we re-elect Barack Obama, Iran will have a nuclear weapon," said Mitt Romney. "And if you elect Mitt Romney, Iran will not have a nuclear weapon."
Rick Santorum has said that the U.S. should plan a military strike against Iran's nuclear facilities and "say to them that if you do not open up those facilities and close them down, we will close them down for you."
Iran has opened two dozen of its facilities to international inspectors, but has refused in defiance of the U.N. Security Council to suspend its uranium enrichment.
A leading hardline Iranian newspaper reported Sunday that Iran has begun uranium enrichment at a new underground site well protected from possible airstrikes.
Kayhan daily, which is close to Iran's ruling clerics, said scientists have begun injecting uranium gas into sophisticated centrifuges at the Fordo facility near the holy city of Qom.
In a talk at a Brookings Institution forum in December, Panetta said an attack on Iran's nuclear facilities would "at best" delay Iran's nuclear program by one or two years. Among the unintended consequences, he said, would be an increase in international support for Iran and the likelihood of Iranian retaliation against U.S. forces and bases in the Mideast.
Panetta did not discuss the issue directly on Sunday's "Face the Nation." But Chairman of the Joint Chiefs of Staff Gen. Martin Dempsey, appearing with the defense secretary, said that he wanted the Iranians to believe that a U.S. military strike could wipe out their nuclear program.
"I absolutely want them to believe that's the case," he said.
Panetta did not rule out launching a pre-emptive strike.
"But the responsible thing to do right now is to keep putting diplomatic and economic pressure on them to force them to do the right thing," he said. "And to make sure that they do not make the decision to proceed with the development of a nuclear weapon."
Panetta said if Iran started developing a weapon, the U.S. would act. "I think they need to know that ? that if they take that step ? that they're going to get stopped."
Dempsey also said that Iran has the military power to block the Strait of Hormuz "for a period of time" if it decides to do so, but that the U.S. would take action to reopen waterway. "We can defeat that," he said.
Panetta said closing the strait would draw a U.S. military response. "We made very clear that the United States will not tolerate the blocking of the Strait of Hormuz," he said. "That's another red line for us and ... we will respond to them."
A number of experts say Iran is unlikely to close the strait, through which Gulf oil flows, because the action could hurt Iran as much as the West.
But a second Iranian newspaper, the Khorasan daily, on Sunday quoted a senior commander of the powerful Revolutionary Guard force as saying Tehran's leadership has decided to order the closure of the strategic oil route if the country's petroleum exports are blocked.
Iranian politicians have issued similar threats in the past, but this is the strongest statement yet by a top commander in the security establishment.
___
Associated Press writer Ali Akbar Dareini in Tehran, Iran, contributed to this report.
ray lewis crystal cathedral sarah vowell fire in reno kelly ripa reno wildfire reno wildfire
Wednesday 11 January 2012
Pakistan's Musharraf to return this month (AP)
KARACHI, Pakistan ? Former President Pervez Musharraf announced Sunday he would return to Pakistan later this month and prepare for elections, something that could add to political turbulence in an already tense atmosphere in the country.
Musharraf's first challenge may be to avoid arrest on his arrival.
On Saturday, state prosecutors said they planned to detain the former army chief on charges he failed to provide security for former Prime Minister Benazir Bhutto ahead of her assassination in 2008. While much remains unpredictable, commentators have speculated that the army will not allow Musharraf to be arrested, setting up fresh conflict between it and the unpopular government of President Asif Ali Zardari.
Musharraf told several thousand supporters in Karachi by telephone on Sunday he would return between Jan. 27 and Jan. 30.
In apparent reference to the charges against him, he said: "I am coming to Pakistan, but there are attempts to scare me off. There are baseless cases against me, but we will face those cases in court."
Musharraf took power in a 1999 coup and stepped down in 2008. He has been living in London and Dubai since then, planning a comeback.
Legal troubles aside, few give him much chance of success.
Musharraf was widely disliked by the time he stepped down, and many of his supporters have since joined other parties.
But he has money, and his army connections still count for something, even if it is unclear whether the current military leadership will support him.
Elections are not scheduled until 2013, but there has been increasing speculation that Zardari may go to the polls this year.
Zardari is under pressure from the military over a memo sent to Washington seeking its help in stopping a supposed coup.
On Saturday, Zardari said he had no intention of stepping down over the memo scandal, as critics have called on him to do.
alaska weather alaska weather election results gop debate live gop debate live nome alaska nome alaska
Tuesday 10 January 2012
Romney sails through Republican debate (Reuters)
GOFFSTOWN, New Hampshire (Reuters) ? Republican Mitt Romney fended off a few attacks on his business record on Saturday and sailed through a high-stakes debate that his rivals used to jockey for position as his conservative alternative in the race for the White House.
Expected to be a punching bag, the former governor of neighboring Massachusetts with a big lead in New Hampshire got a major break as his main rivals stopped short of going all-out negative against him and instead squabbled among themselves.
This leaves Romney in a strong position in New Hampshire, where polls show him winning the primary handily on Tuesday. That would put more pressure on his rivals to try to stop him at the next contest in South Carolina, where he also has a small lead.
Looking cool and confident with hands in his pockets, Romney repeatedly positioned himself above the fray. He stuck to lines from his campaign stump speech and trained fire on the man he wants to replace in November's election, Democratic President Barack Obama.
"I don't want to be critical of the people on this stage," Romney said at the first of two back-to-back debates that represent the last chance to sway large numbers of voters before New Hampshire votes in its Republican primary on Tuesday.
A similar performance at a second debate in Concord on Sunday will help him close the deal in New Hampshire and put him in a strong position in South Carolina on January 21, where a victory could give him a virtual lock on the Republican presidential nomination.
For the most part the debate was about the battle for second place in New Hampshire and for the conservative vote in South Carolina, where Romney's rivals hope to slow him down.
To that end, former Pennsylvania Senator Rick Santorum, who soared as the conservative alternative to Romney when he came in a close second in Iowa's caucuses last week, may have helped himself with conservative voters.
SANTORUM GETS HIS CHANCE
Taking center stage for the first time after serving as a second-tier candidate all year, Santorum displayed a wide range of policy views and stuck to his opposition to gay rights and the Supreme Court's 1973 Roe v. Wade decision that legalized abortion.
"I am for overturning Roe versus Wade. I do not believe that we have a right in this country, in the Constitution, to take a human life. I don't think that's -- I don't think our founders envisioned that," Santorum said.
Libertarian congressman Ron Paul, hoping to thwart Santorum's rise and hang on to second place in New Hampshire, tried to raise doubts about Santorum's conservative credentials by pointing toward his predilection for securing massive amounts of government aid for his home state.
Santorum has come under scrutiny for a long history of obtaining taxpayer dollars for Pennsylvania for what critics call wasteful projects like $500,000 for a polar bear exhibit at the Pittsburgh zoo.
"To say you're a conservative is a stretch, but you've convinced a lot of people," Paul told Santorum.
Santorum seemed to take Paul's broadside in stride. He defended his practices, saying he made sure Pennsylvania got a fair share of the money its taxpayers sent to the federal government and "I don't apologize for that."
And in a discussion on Iran, Santorum sharply criticized Paul's non-interventional view toward foreign entanglements, when Paul said he liked that the U.S. Navy had picked up some Iranian fishermen stranded in the Arabian Sea.
"This is the kind of stuff we should deal with," said Paul. Santorum quickly retorted: "Well, Ron, if we had your foreign policy, there wouldn't have been a fleet there to pick up the Iranian fishermen."
HUNTSMAN, GINGRICH GRAPPLE
Jon Huntsman, the former U.S. ambassador to China who skipped Iowa to focus on New Hampshire, accused Romney of trying to instigate a trade war with China with frequent salvos over China's currency policies.
Huntsman moved into second place in New Hampshire in a poll published on Saturday and needs a big performance to score a breakthrough.
Romney reminded viewers that Huntsman had served in China under Obama.
"I'm sorry, Governor, you were, the last two years, implementing the policies of this administration in China. The rest of us on this stage were doing our best to get Republicans elected across the country and stop the policies of this president from being put forward," Romney said.
At the beginning, the debate looked like it could turn out as advertised, a free-for-all against Romney in hopes to slowing him down.
As Romney's leadership of the private equity firm Bain Capital comes under scrutiny, Santorum said just because Romney has business experience does not mean he is qualified to serve as the American president.
Former speaker of the U.S. House of Representatives Newt Gingrich, bitter about losing his front-runner status after he was subjected to massive attack ads by Romney and his supporters before Iowa, questioned Romney's leadership at Bain Capital.
Romney points to his business experience as a selling point during troubled economic times, but his opponents see his leadership of Bain Capital as a negative. The company bought troubled companies and restructured them, sometimes resulting in layoffs and facility closures.
"The governor has every right to defend that," Gingrich said. "But I think it's a legitimate part of the debate to say OK on balance are people better off by this particular style of investment?"
Romney said in the world of private-sector business, sometimes investments work, and sometimes they do not.
(Additional reporting by Sam Youngman; Editing by Mary Milliken and Christopher Wilson)
we bought a zoo ipad accessories derrick rose port charlotte florida kit homes boxing day radio shack
Sunday 8 January 2012
Fugitive murder suspect wanted in Spain captured on Florida Turnpike
A 37-year-old Cuban man, who is wanted in Spain for murder and robbery, was arrested on Florida's Turnpike after a routine traffic stop, the U.S. Marshals Service said this week.
Abdel Roca Teijelo is the subject of an international arrest warrant issued Aug. 30. He was captured Dec. 30 near the Snapper Creek Plaza, according to U.S. Immigration and Customs Enforcement's Homeland Security Investigations agents.
An investigation by Spanish law enforcement authorities revealed that on June 30, neighbors of a coffee shop located on Calle Navas de Tolosa in Saragossa, Spain, called the fire department because of a strong odor coming from the building, according to a provisional arrest warrant filed with the court.
Firefighters went to the caf? and discovered a large sarcophagus containing the body of Ruben Joaquin Fauste Elvira, Teijelo's boss, and an ax. An examination of the body determined that the cause of death was multiple ax wounds to the head, court records stated.
Spanish authorities discovered that Teijelo and an accomplice both worked for the victim at a number of coffee shops. Detectives also reviewed cellphone records for Teijelo and his accomplice and discovered a meeting was set up for Elvira, Teijelo and Teijelo's accomplice at the cafe sometime between 7:30 p.m. June 10 and 12:30 a.m. June 11. The victim was never heard from again, according to court records.
Spanish investigators also learned that on June 13, the accomplice rented two vans and purchased building materials, and with the assistance of Teijelo brought the materials to the cafe. The authorities later discovered that some of those building materials were used to construct the sarcophagus that would eventually be used to hide the victim's body and the ax used to kill him, agents said.
The U.S. Marshals Service is holding Roca Teijelo in custody until he can be turned over to law enforcement authorities in Spain.
Source: http://www.miamiherald.com/2012/01/07/2578235/fugitive-murder-suspect-wanted.html
vanguardngrnews: Bomb Blast: Israel to help FG tackle Boko Haram http://t.co/1qj6P6PJ
- Passer la navigation
- Twitter sur votre mobile ? Cliquez ici m.twitter.com!
- Passer cette ?tape
- Connexion
Bomb Blast: Israel to help FG tackle Boko Haram dlvr.it/13w7Kd 
vanguardngrnews Vanguard Newspapers
Pied de page
Source: http://twitter.com/vanguardngrnews/statuses/155467958632718336
kawasaki disease mega millions emma stone texas longhorns texas longhorns bill maher francesca woodman
Thursday 5 January 2012
Wednesday 4 January 2012
Vaja iVolution Top LP Leather iPhone 4S Flip Case Amazes All
Vaja continues to out one of the most incredible, luxurious leather cases for the iPhone, and this time it has released the iVolution Top LP. A two-tone leather flip-style case made to fit both the iPhone 4S and iPhone 4 priced at $95. The iVolution Top LP has a flap that keeps the iPhone's screen protect while not in use and flips down and over the back when you want to use it. One half is made with Vaja's special Floater leather while the other is made from a smoother Caterina type of leather for the exterior, and Caterina leather interior. The camera cutout around the back is designed to insure flawless picture taking using the LED flash without any glare. Like all Vaja's cases, this one is customizable with a slew of different leather colors and leather types.
If you're thinking about handing over your cash, we can assure you all that leather goodness will be worth your while having reviewed Vaja's iPad 2 folio.
Source: http://www.gadgetmac.com/news/vaja-ivolution-top-lp-leather-iphone-4s-flip-case-amazes-all.html
regis philbin last show regis philbin last show ray lewis crystal cathedral sarah vowell fire in reno kelly ripa
Tuesday 3 January 2012
Iran dismisses U.S. sanctions on its Central Bank: report (Reuters)
TEHRAN (Reuters) ? Iran dismissed on Sunday Washington's move to impose new sanctions on financial institutions dealing with the Islamic state's central bank over the country's disputed nuclear program, the Students news agency reported.
President Barack Obama signed the bill, approved by Congress
last week, which aims to reduce Tehran's oil revenues but gives the U.S. president powers to waive penalties as required.
The head of Iran's Chamber of Commerce, Mohammad Nahavandian, rejected the move as "unjustifiable," saying such sanctions would have reciprocal consequences.
"The Iranian nation and those involved in trade and economic activities will find other alternatives," said Nahavandian.
Washington and the European Union have already pushed four rounds of sanctions through the United Nations over Iran's nuclear program and imposed unilateral measures that have deterred Western investment in Iran's oil sector, making it harder to move money in and out of the country.
Imposing sanctions on the central bank would tighten that screw and make it more difficult for Iran to receive payments for exports -- particularly oil, a vital source of hard currency for the world's fifth-biggest crude exporter.
Iranian officials insist that foreign sanctions have had no impact on the country's economy.
"The sanctions have raised the cost of trade and economic transactions but it has not managed to change Iran's political behavior," Nahavandian said.
So far, Iran's leaders have shown no sign of changing the country's nuclear course despite mounting international pressure to force it to stop.
U.S. financial institutions are already generally prohibited from doing business with any bank in Iran, including the central bank, so the new measure by Washington would have to be carried out with international agreement.
Nahavandian said European countries should not miss the investment opportunity in an emerging market like Iran.
"Considering the economic crisis in Europe, the European companies are after finding new markets ... political disputes should not have an impact on trade relations," he said.
Senior U.S. officials said Washington was engaging with its foreign partners to ensure the sanctions can work without harming global energy markets and stressed the U.S. strategy for engaging with Iran was unchanged by the bill.
Washington and its allies say Iran is trying to build nuclear bombs under the cover of a civilian program. Tehran denies that, saying it needs nuclear technology to generate power.
(Reporting by Parisa Hafezi; Editing by Paul Tait)
mike leach mike leach billy graham scion fr s elf on a shelf elf on a shelf carrier iq
Sunday 1 January 2012
???????? ?1st JAPAN CONCERT TOUR ?BLACK MOUNTAIN?? ??????!
????????
?????????????????
1st JAPAN CONCERT TOUR ?BLACK MOUNTAIN?????
??????? ?????MAP??????
2012/03/02(?)?18:30?(17:30???)???????????
????
6??????6???????????(?????????)?TANK!????????????????????????????
Source: http://www.sundayfolk.com/livlog/6fvbqc6/
toys r us shame shame denver weather donovan mcnabb donovan mcnabb the waltons
Subscribe to:
Posts (Atom)